本文選題：2型糖尿病 + 亞臨床甲狀腺功能減退癥　； 參考：《山西醫(yī)科大學(xué)》2015年碩士論文

【摘要】：目的:探討2型糖尿病合并亞臨床甲狀腺功能減退患者炎癥因子TNF-α、IL-6、ICAM-1水平變化特點及其意義。方法:按照入組標準選取2014年10月至2015年3月山西醫(yī)科大學(xué)第一附屬醫(yī)院內(nèi)分泌科門診及住院患者和健康體檢者100例,分為四組:正常對照組10例(NC組),2型糖尿病組30例(T2DM組),亞臨床甲減組30例(SCH組),2型糖尿病合并亞臨床甲減組30例(T2DM+SCH組)。上述四組病例均排除原發(fā)性高血壓、心臟疾病、肝臟疾病、慢性腎臟疾病、糖尿病合并的嚴重并發(fā)癥等。記錄研究對象的性別、年齡、診斷、現(xiàn)病史、既往史等,測定血清FT3、FT4、TSH、Hb A1c,酶聯(lián)免疫吸附法(ELISA)法檢測各組血清TNF-α、IL-6、ICAM-1水平,分析2型糖尿病合并亞臨床甲狀腺減退癥患者血清TNF-α、IL-6、ICAM-1水平變化。結(jié)果:與NC組相比,其余三組TNF-α、IL-6及ICAM-1表達水平均增高,差異有統(tǒng)計學(xué)意義(P均0.05)。其中T2DM+SCH組TNF-α、IL-6表達水平最為顯著(P0.05),而T2DM組與SCH組相比差異無統(tǒng)計學(xué)意義;SCH組ICAM-1表達水平最低(P0.05),且T2DM組與T2DM+SCH組相比差異無統(tǒng)計學(xué)意義。結(jié)論:1.2型糖尿病患者合并亞甲減后TNF-α、IL-6水平顯著增高,其可能存在共同的慢性炎癥起源。2.TNF-α、IL-6有可能成為評估2型糖尿病合并亞甲減患者大血管病變發(fā)病風(fēng)險的早期診斷標志物,從而為臨床診療提供指導(dǎo)。
[Abstract]:Objective: to investigate the changes and significance of inflammatory factor TNF- 偽 IL-6 in patients with type 2 diabetes mellitus complicated with subclinical hypothyroidism. Methods: from October 2014 to March 2015, 100 outpatients and inpatients in the Department of Endocrinology, the first affiliated Hospital of Shanxi Medical University, were selected according to the group criteria. The patients were divided into four groups: normal control group (n = 10) and subclinical hypothyroidism group (n = 30) with type 2 diabetes mellitus and subclinical hypothyroidism group (n = 30) respectively. There were 30 cases with type 2 diabetes mellitus complicated with subclinical hypothyroidism in the subclinical hypothyroidism group (n = 30). The four groups excluded essential hypertension, heart disease, liver disease, chronic kidney disease and severe complications of diabetes mellitus. The sex, age, diagnosis, present history, past history of the subjects were recorded. The serum levels of TNF- 偽 -TSHHbA1cand Elisa were measured by Elisa, and the levels of TNF- 偽 IL-6 and ICAM-1 were measured by Elisa. The changes of serum TNF- 偽 IL-6 and ICAM-1 levels in patients with type 2 diabetes mellitus complicated with subclinical hypothyroidism were analyzed. Results: compared with NC group, the expression levels of TNF- 偽 IL-6 and ICAM-1 in the other three groups were higher than those in NC group (P < 0.05). The expression of TNF- 偽 IL-6 in T2DM SCH group was the most significant, but there was no significant difference between T2DM group and SCH group. There was no significant difference in ICAM-1 expression level between Sch group and SCH group, and there was no significant difference between T2DM group and T2DM SCH group. Conclusion the level of TNF- 偽 and IL-6 in type 1.2 diabetic patients with hypothyroidism is significantly higher than that in patients with type 1. 2. TNF- 偽 IL-6 may be an early diagnostic marker for assessing the risk of macroangiopathy in patients with type 2 diabetes mellitus with hypothyroidism. So as to provide guidance for clinical diagnosis and treatment.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R587.1;R581.2

【參考文獻】

相關(guān)期刊論文 前2條

1 馮琨;杜馥曼;王丹;楊玉芝;;IGT患者IL-6、TNF-α與胰島素抵抗的相關(guān)性分析[J];放射免疫學(xué)雜志;2009年02期

2 盛志新;謝丹紅;孫遼;舒曉春;葉禮紅;沈晶;魯紅云;;2型糖尿病患者血漿炎癥因子水平與糖代謝及胰島素抵抗的關(guān)系[J];中國糖尿病雜志;2010年04期

，

本文編號：1903452